ic arthritis, and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa (HS).21-27 Zasocitinib is an investigational compound that has not been approved for use by any regulatory authority.

About the LATITUDE Atlas Study
The LATITUDE Atlas (NCT06973291 / TAK-279-PsO-3004) study is a Phase 3, randomized, multicenter, double-blind trial evaluating the efficacy, safety and tolerability of zasocitinib compared to deucravacitinib in adult participants with moderate-to-severe plaque psoriasis.28 The study enrolled 606 participants, who received zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily up to week 16.28 Participants were in the study for up to 25 weeks, which included a screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period. The primary endpoint was the percentage of participants achieving PASI 100 at week 16.28

About Tyrosine Kinase 2 (TYK2) Inhibitors

=*=*=*=*=*=
当前为第6/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页